Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: An expert taskforce review

Jesús Garciá-Foncillas; E. Alba; E. Aranda; E. Diáz-Rubio; R. López-López; J. Tabernero; A. Vivancos

doi:10.1093/annonc/mdx501

Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: An expert taskforce review

Jesús Garciá-Foncillas, E. Alba, E. Aranda, E. Diáz-Rubio, R. López-López, J. Tabernero, A. Vivancos

Department of Medicine

Research output: Contribution to journal › Review article › Research › peer-review

28 Citations (Scopus)

Abstract

© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. The importance of mutation identification for advanced colorectal cancer treatment with anti-epidermal growth factor receptor agents is well established. However, due to delays in turnaround time, low-quality tissue samples, and/or lack of standardization of testing methods a significant proportion of patients are being treated without the information that Kirsten rat sarcoma and neuroblastoma rat sarcoma (RAS) testing can provide. The detection of mutated circulating tumor DNA by BEAMing technology addresses this gap in care and allows these patients to receive international guideline-recommended expanded RAS testing with rapid turnaround times. Furthermore, the overall concordance between OncoBEAM RAS colorectal cancer testing and standard of care tissue testing is very high (93.3%). This article presents an overview of the clinical utility and potential applications of this minimally invasive method, such as early detection of emergent resistance to anti-epidermal growth factor receptor therapy. If appropriately implemented, BEAMing technology holds considerable promise to enhance the quality of patient care and improve clinical outcomes.

Original language	English
Pages (from-to)	2943-2949
Journal	Annals of Oncology
Volume	28
Issue number	12
DOIs	https://doi.org/10.1093/annonc/mdx501
Publication status	Published - 1 Dec 2017

Keywords

Colorectal cancer
EGFR
Liquid biopsy
Mutation testing
Tumor resistance

Access to Document

10.1093/annonc/mdx501

Fingerprint Dive into the research topics of 'Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: An expert taskforce review'. Together they form a unique fingerprint.

Cite this

@article{a807351a8efc4401911589a8dd2f2f3f,

title = "Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: An expert taskforce review",

abstract = "{\textcopyright} The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. The importance of mutation identification for advanced colorectal cancer treatment with anti-epidermal growth factor receptor agents is well established. However, due to delays in turnaround time, low-quality tissue samples, and/or lack of standardization of testing methods a significant proportion of patients are being treated without the information that Kirsten rat sarcoma and neuroblastoma rat sarcoma (RAS) testing can provide. The detection of mutated circulating tumor DNA by BEAMing technology addresses this gap in care and allows these patients to receive international guideline-recommended expanded RAS testing with rapid turnaround times. Furthermore, the overall concordance between OncoBEAM RAS colorectal cancer testing and standard of care tissue testing is very high (93.3%). This article presents an overview of the clinical utility and potential applications of this minimally invasive method, such as early detection of emergent resistance to anti-epidermal growth factor receptor therapy. If appropriately implemented, BEAMing technology holds considerable promise to enhance the quality of patient care and improve clinical outcomes.",

keywords = "Colorectal cancer, EGFR, Liquid biopsy, Mutation testing, Tumor resistance",

author = "Jes{\'u}s Garci{\'a}-Foncillas and E. Alba and E. Aranda and E. Di{\'a}z-Rubio and R. L{\'o}pez-L{\'o}pez and J. Tabernero and A. Vivancos",

year = "2017",

month = dec,

day = "1",

doi = "10.1093/annonc/mdx501",

language = "English",

volume = "28",

pages = "2943--2949",

number = "12",

}

Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: An expert taskforce review. / Garciá-Foncillas, Jesús; Alba, E.; Aranda, E.; Diáz-Rubio, E.; López-López, R.; Tabernero, J.; Vivancos, A.

In: Annals of Oncology, Vol. 28, No. 12, 01.12.2017, p. 2943-2949.

Research output: Contribution to journal › Review article › Research › peer-review

TY - JOUR

T1 - Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: An expert taskforce review

AU - Garciá-Foncillas, Jesús

AU - Alba, E.

AU - Aranda, E.

AU - Diáz-Rubio, E.

AU - López-López, R.

AU - Tabernero, J.

AU - Vivancos, A.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. The importance of mutation identification for advanced colorectal cancer treatment with anti-epidermal growth factor receptor agents is well established. However, due to delays in turnaround time, low-quality tissue samples, and/or lack of standardization of testing methods a significant proportion of patients are being treated without the information that Kirsten rat sarcoma and neuroblastoma rat sarcoma (RAS) testing can provide. The detection of mutated circulating tumor DNA by BEAMing technology addresses this gap in care and allows these patients to receive international guideline-recommended expanded RAS testing with rapid turnaround times. Furthermore, the overall concordance between OncoBEAM RAS colorectal cancer testing and standard of care tissue testing is very high (93.3%). This article presents an overview of the clinical utility and potential applications of this minimally invasive method, such as early detection of emergent resistance to anti-epidermal growth factor receptor therapy. If appropriately implemented, BEAMing technology holds considerable promise to enhance the quality of patient care and improve clinical outcomes.

AB - © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. The importance of mutation identification for advanced colorectal cancer treatment with anti-epidermal growth factor receptor agents is well established. However, due to delays in turnaround time, low-quality tissue samples, and/or lack of standardization of testing methods a significant proportion of patients are being treated without the information that Kirsten rat sarcoma and neuroblastoma rat sarcoma (RAS) testing can provide. The detection of mutated circulating tumor DNA by BEAMing technology addresses this gap in care and allows these patients to receive international guideline-recommended expanded RAS testing with rapid turnaround times. Furthermore, the overall concordance between OncoBEAM RAS colorectal cancer testing and standard of care tissue testing is very high (93.3%). This article presents an overview of the clinical utility and potential applications of this minimally invasive method, such as early detection of emergent resistance to anti-epidermal growth factor receptor therapy. If appropriately implemented, BEAMing technology holds considerable promise to enhance the quality of patient care and improve clinical outcomes.

KW - Colorectal cancer

KW - EGFR

KW - Liquid biopsy

KW - Mutation testing

KW - Tumor resistance

U2 - 10.1093/annonc/mdx501

DO - 10.1093/annonc/mdx501

M3 - Review article

VL - 28

SP - 2943

EP - 2949

IS - 12

ER -